Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Aeglea Bio Therapeutics stock in Canada

Own Aeglea Bio Therapeutics shares in just a few minutes.

Aeglea Bio Therapeutics is a biotechnology business based in the US. Aeglea Bio Therapeutics stocks (AGLE.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $7.13 – an increase of 19.27% over the previous week. Aeglea Bio Therapeutics employs 92 staff and has a trailing 12-month revenue of around $7 million.

How to buy stocks in Aeglea Bio Therapeutics

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – AGLE – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Aeglea Bio Therapeutics stock price (NASDAQ:AGLE)

Use our graph to track the performance of AGLE stocks over time.

Aeglea Bio Therapeutics shares at a glance

Information last updated 2022-09-24.
Latest market close$0.53
52-week range$0.37 - $8.50
50-day moving average $0.49
200-day moving average $1.97
Wall St. target price$3.58
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.09

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 5 of 5
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95–$6.95
$0 if conditions met, else $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Young investors 18 to 24 can get free online trades and a $0 annual account fee. Conditions apply.
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
min $1.00, max 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
FREE TRADES
Wealthsimple
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get $25 when you open a Wealthsimple account and fund at least $150.
OFFER
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get almost $500 in commission free trades when you fund your new account with a minimum of $10,000. Conditions apply. Ends October 31, 2022.
loading

Compare up to 4 providers

Is it a good time to buy Aeglea Bio Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Aeglea Bio Therapeutics price performance over time

Historical closes compared with the close of $0.526 from 2022-09-30

1 week (2022-09-21) N/A
1 month (2022-08-29) N/A
3 months (2022-07-01) 3.12%
6 months (2022-03-29) N/A
1 year (2021-09-28) N/A
2 years (2020-10-02) -92.51%
3 years (2019-10-02) 7.51
5 years (2017-10-02) 5.01

Aeglea Bio Therapeutics financials

Revenue TTM $7 million
Gross profit TTM $-38,330,000
Return on assets TTM -43.16%
Return on equity TTM -86.14%
Profit margin 0%
Book value $1.38
Market capitalisation $27 million

TTM: trailing 12 months

Aeglea Bio Therapeutics share dividends

We're not expecting Aeglea Bio Therapeutics to pay a dividend over the next 12 months.

Aeglea Bio Therapeutics share price volatility

Over the last 12 months, Aeglea Bio Therapeutics's shares have ranged in value from as little as $0.372 up to $8.5. A popular way to gauge a stock's volatility is its "beta".

AGLE.US volatility(beta: 1.66)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aeglea Bio Therapeutics's is 1.6576. This would suggest that Aeglea Bio Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Aeglea Bio Therapeutics overview

Aeglea BioTherapeutics, Inc. , a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015.

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site